Product Description
A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of 225Ac-PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by a cytotoxic dose of alpha radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/actinium-ac-225-psma-r2)
Mechanisms of Action: Radiopharmaceutical, PSMA
Novel Mechanism: No
Modality: Radiopharmaceutical
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, France, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05983198 |
SatisfACtion | P1 |
Active, not recruiting |
Prostate Cancer |
2031-03-04 |
12% |
2026-06-30 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|